OSR Health Faces Crucial Nasdaq Deadline as Stock Price Lags

OSR Health Faces Crucial Nasdaq Deadline as Stock Price Lags

2026-08-11 companies

New York, Tuesday, 11 August 2026.
Facing a critical August 18 deadline to maintain its Nasdaq listing, OSR Health’s chief executive is rejecting a reverse stock split, relying on operational growth and subsidiary licensing deals.

OSR Health, Inc. (NASDAQ: OSRH) is facing a critical window to address its listing status on the Nasdaq Stock Market [1][3]. Under Nasdaq rules, the global healthcare holding company must regain the minimum bid price requirement of $1.00 per share [1]. On August 11, 2026, Chief Executive Officer Peter Hwang issued a letter to shareholders noting that today marks precisely five business days before the August 18, 2026, deadline [1]. By this date, Nasdaq is expected to communicate its determination regarding OSR Health’s continued listing if its stock price fails to recover [1]. The company’s stock closed at $0.4106 on August 10, 2026 [5][7], and experienced a modest pre-market uptick to $0.4185 on August 11, 2026 [5], representing a change of 1.924%.

Avoiding the Split and Funding R&D

Despite the persistent downward pressure on the stock, OSR Health has formally announced that it will not execute a reverse stock split to artificially inflate its share price and regain regulatory compliance [3][8]. Instead, the Delaware-incorporated firm plans to focus entirely on its commercial operations and business development to drive organic growth [3][8]. This decision comes during what Hwang acknowledged as one of the most difficult years in the company’s history [1]. To support the cash-burning research and development (R&D) operations of its subsidiaries, Hwang highlighted that he has committed substantial personal capital through multiple rounds of financing [1]. Currently, the company maintains a tight liquidity position, holding $1.57 million in cash against $4.95 million in total debt [5], which results in a net cash position of -3.38 million.

Subsidiary Pipeline and Licensing Opportunities

To generate non-dilutive revenue and unlock shareholder value, OSR Health is actively pursuing strategic transactions across its portfolio [1]. The company, which specializes in immuno-oncology, regenerative biologics, and medical device technologies, revealed that two unnamed subsidiaries have received inbound inquiries regarding potential technology and product out-licensing [1]. One of these subsidiaries is currently negotiating a preliminary term sheet, while the other is in the early stages of discussion [1]. These efforts run parallel to OSR Health’s broader expansion strategy, which includes its definitive Asset Purchase Agreement to acquire the global intellectual property portfolio of VXM01 from VAXIMM AG for $30 million [3][8]. This acquisition, which includes patents, clinical data, and manufacturing know-how, provides patent protection extending through the year 2038 [3][8].

CVR Program Clarifications and Governance Milestones

In addition to its operational push, OSR Health recently addressed market rumors regarding its Shareholder Loyalty Contingent Value Rights (CVR) program [2]. On August 7, 2026, the company issued a clarification statement regarding its prior July 31, 2026, announcement [2]. OSR Health emphasized that Nasdaq has not approved or endorsed the loyalty CVR program [2]. Instead, Nasdaq’s previous input was strictly limited to a technical inquiry regarding whether the program would trigger a mechanical stock price adjustment, such as an ex-date adjustment [2]. The company confirmed that the record date for the Shareholder Loyalty CVR program remains unchanged for August 14, 2026 [2].

Shareholder Support and Corporate Restructuring

The strategic transition follows a formal corporate rebranding; the company officially changed its name from OSR Holdings to OSR Health, Inc. on June 11, 2026, to better align with its focus on biotechnology, medical technology, life sciences, and wellness [3][8]. This corporate momentum was further reinforced during the company’s annual stockholder meeting held on August 7, 2026 [4][8]. Stockholders representing 21,088,120 shares—constituting approximately 60.05% of the 35,118,692 outstanding common shares as of the July 8, 2026, record date—were present to establish a quorum [4][8]. Shareholders overwhelmingly approved all key proposals, including the re-election of seven directors to serve until 2027, the ratification of the independent auditor, and an Authorized Shares Increase Proposal [3][4][8]. While this authorized share increase grants the company additional capacity, OSR Health reported no immediate plans for share issuance or dilution [4].

Sources


Nasdaq compliance Healthcare sector